ClinicalTrials.gg
CompletedNCT01165203Updated Apr 30, 2018Results posted

Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects

A Phase 2 interventional study of Herpes Zoster Vaccine GSK1437173A and Placebo in Herpes Zoster, sponsored by GlaxoSmithKline. Completed at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-30.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.

Enrollment
30th of 46
123 · median 239
Started
2010
with 3 others
Phase 2
8 of 46
1 open now
Registered
4th of 46
by date
Lead sponsor
26 of 46
GlaxoSmithKline

Among the 46 studies testing shingrix in Herpes Zoster, this one is the 30th largest by enrollment, is one of 4 that started in 2010, is one of 8 in phase 2, and was the 4th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About shingrix

shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing shingrix in Herpes Zoster, or all of them as a file.
02

Study summary

This observer-blind study will evaluate the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' investigational Herpes Zoster (HZ) vaccine GSK1437173A in Human Immunodeficiency Virus (HIV) infected subjects, firstly enrolling subjects treated with antiretroviral therapy (ART) and with high CD4 T cell counts, and subsequently ART-treated subjects with low CD4 T cell counts, and ART-naïve subjects with high CD4 T cell counts.

This Protocol Posting has been updated following Amendment 1 of the Protocol, August 2010. The impacted sections is exclusion criteria.

03

Conditions studied

  • Herpes Zoster

Browse trials for

Keywords

  • immunogenicity
  • vaccine
  • safety
  • HIV
  • Herpes Zoster
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol;
  • Male and female subjects at least 18 years old at the time of vaccination;
  • Subjects born before 1985 and not from a tropical region. Subjects born in 1985 or later and subjects born before 1985 in tropical regions must have a history of Varicella Zoster virus (VZV) infection or serological evidence of prior VZV infection;
  • Written obtained from the subject;
  • Female subjects of non- may be enrolled in the study; Non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or .

OR Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate for 30 days prior to vaccination, and has a negative pregnancy test on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series;

  • Known to be -1 (HIV-1) infected, diagnosed at least 1 year prior to enrolment;
  • For the antiretroviral therapyART High CD4 and ART Low CD4 cohorts:

    • Stable on ART for at least one year
    • >= 50 cells /mm3 at screening
    • Undetectable VL at screening;
  • For the non-ART High CD4 cohort:

    • ART-naïve subjects who have never received anti-retroviral therapy after HIV diagnosis and for whom commencement of ART is not expected based on current assessment within next seven months;
    • HIV VL >= 1000 copies/mL and \<= 100 000 copies/mL at screening
    • CD4 T cell count >= 500 cells/mm3 at screening.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period;
  • Vaccination against varicella or herpes zoster (HZ) within the previous 12 months;
  • Occurrence of a varicella or HZ episode within the previous 12 months;
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Additionally, consider allergic reactions to other material or equipment related to study participation. Please note, the vaccine and vials in this study do not contain latex;
  • Has currently an Acquired Immunodeficiency Syndrome (AIDS) defining condition;
  • Opportunistic infection or AIDS-associated in the previous year;
  • Any confirmed or suspected or immunodeficient condition resulting from disease other than infection or immunosuppressive/cytotoxic therapy;
  • Administration of immunoglobulins, and/or any blood products within 90 days preceding the first dose of study vaccine/placebo or planned administration during the study period;
  • Chronic administration of immunosuppressive or other immune-modifying drugs within 6 months prior to the first vaccine dose;
  • Administration and/or planned administration of a vaccine not foreseen by the study protocol within 30 days before dose 1, dose 2 and/or 3 of vaccine and/or within 30 days after any dose. However, licensed non-replicating vaccines may be administered up to 8 days prior to dose 1, 2 and/or 3, and/or at least 14 days after any dose of study vaccine;
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product;
  • Acute disease at the time of enrolment;
  • Any to receiving intramuscular injections;
  • Any condition or illness which might interfere with the evaluation of the safety or immunogenicity of the vaccine;
  • Active (HBV) infection or active (HCV) infection.
  • Current use of HIV fusion inhibitors, chemokine (C-C motif) receptor (CCR5) inhibitors or Interleukin-2/ Interleukin-7/ Interferon;
  • For subjects in the ART cohorts, any change in anti-retroviral drug regimen within 12 weeks prior to vaccination;
  • Pregnant or lactating female;
  • Female planning to become pregnant or planning to discontinue precautions;
  • Abnormal biochemical and hematological laboratory values obtained for blood samples collected at screening.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    GSK1437173A Group

    Subjects who received three doses of GSK1437173A vaccine (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.

    Biological: Herpes Zoster Vaccine GSK1437173A

  • Placebo comparator
    Placebo Group

    Subjects who received three doses of placebo (Months 0, 2 and 6), administered intramuscularly, in the deltoid muscle of the non-dominant arm.

    Biological: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From Month 0 to Month 18

  2. Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From screening (up to 21 days prior to Month 0) until Month 18

  3. Number of Subjects With Any Fatal SAEs

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: From screening (up to 21 days prior to Month 0) until Month 18

  4. Number of Subjects With Any Adverse Events (AEs) of Specific Interest

    AEs of specific interest include new onset of autoimmune diseases (NOADs) and other immune mediated inflammatory disorders from administration of the first dose of vaccine/placebo.

    Time frame: From Month 0 until Month 18

  5. Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = incidence of a particular symptom regardless of their intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

    Time frame: Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  6. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, gastrointestinal (symptoms included nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and temperature \[defined as oral/axillary temperature above (\>) 37.5 degrees Celsius (°C)\]. Any = incidence of a particular symptom regardless of their intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

    Time frame: Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses

  7. Number of Subjects With Unsolicited AEs

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: Within 30 days (Days 0-29) after each vaccination

  8. Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

    The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.

    Time frame: At Screening Visit (up to 21 days prior to Month 0)

  9. Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

    The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.

    Time frame: At Month 1

  10. Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

    The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.

    Time frame: At Month 2

  11. Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

    The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also staus unknown.

    Time frame: At Month 3

  12. Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

    The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.

    Time frame: At Month 6

  13. Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

    The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also staus unknown.

    Time frame: At Month 7

  14. Number of Subjects With Any Significant Change in Antiretroviral Therapy (ART), Including Initiation of ART in ART-naïve Subjects

    In this analysis, results were tabulated for the main study groups. Significant changes to ART appeared due to failure to control HIV viral load and due to failure to maintain high CD4 cells count.

    Time frame: From Month 0 until Month 18

  15. Number of Subjects With Any AIDS-defining Condition

    In this analysis, results were tabulated for the main study groups.

    Time frame: From Month 0 until Month 18

  16. Number of Subjects With Any Pre-defined Changes in HIV Viral Load (VL) and CD4 T-cell Count

    In this analysis, results were tabulated for the main study groups.

    Time frame: From Month 1 to Month 7

  17. Number of Subjects With Any Significant Change in Antiretroviral Therapy (ART), Including Initiation of ART in ART-naïve Subjects, by HIV Status

    In this analysis, results were tabulated by HIV status

    Time frame: From Month 0 to Month 18

  18. Number of Subjects With Any AIDS-defining Condition, by HIV Status

    In this analysis, results were tabulated by HIV status

    Time frame: From Month 0 to Month 18

  19. Number of Subjects With Any Pre-defined Changes in HIV Viral Load (VL) and CD4 T-cell Count, by HIV Status

    In this analysis, results were tabulated by HIV status.

    Time frame: From Month 1 to Month 7

  20. Frequency of gE-specific CD4 T-cells

    The analysis focused on CD4 T-cells expressing at least 2 cytokines (among interferon-gamma (IFN-g) , interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-a) and/or CD40 ligand (CD40L)) as determined by in vitro intracellular cytokine staining (ICS) at Month 7 in ART and non-ART cohorts presenting high CD4 counts at enrollment.

    Time frame: At Month 7

  21. -Anti-gE Antibody (Ab) Concentrations

    -Anti-gE antibody (Ab) concentrations were determined by Enzyme-Linked Immunosorbent Assay (ELISA) at Month 7 in ART and non-ART cohorts presenting high CD4 counts at enrolment. Antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).

    Time frame: At Month 7

Secondary outcomes

  1. -Frequencies of Varicella-Zoster Virus (VZV)- and gE-specific CD4 T-cells

    The analysis focused on CD4 T cells expressing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L as determined by ICS at Months 0, 1, 2, 3, 6, 7 and 18 and tabulated for the main study groups.

    Time frame: At Month 0, 1, 2, 3, 6, 7 and 18

  2. -Frequencies of Varicella-Zoster Virus (VZV)- and gE-specific CD4 T-cells, by HIV Status

    The analysis focused on CD4 T-cells expressing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L as determined by ICS at Months 0, 1, 2, 3, 6, 7 and 18 and tabulated by HIV status.

    Time frame: At Months 0, 1, 2, 3, 6, 7 and 18

  3. -Anti-VZV and Anti-gE Antibody Concentrations

    Antibody concentrations were as determined by ELISA and tabulated for the main study groups. Anti-VZV and anti-gE antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL.

    Time frame: At Months 0, 1, 2, 3, 6, 7 and 18

  4. -Anti-VZV and Anti-gE Antibody Concentrations, by HIV Status

    Antibody concentrations were as determined by ELISA and tabulated by HIV status. Anti-VZV and anti-gE antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL.

    Time frame: At Months 0, 1, 2, 3, 6, 7 and 18

  5. Number of Subjects With Any Herpes Zoster (HZ) Cases and Complications

    Time frame: From Month 0 until Month 18

  6. CD4 Count

    CD4 count was tabulated by HIV status.

    Time frame: At Screening Visit (up to 21 days prior to Month 0), Months 1, 2, 3, 6, 7 and 18

  7. HIV VL

    HIV VL was tabulated by HIV status, for subjects with a number of available results greater than or equal to (≥) 40 copies/mL.

    Time frame: At Screening Visit (up to 21 days prior to Month 0), Months 1, 2, 3, 6, 7 and 18

07

Results

Posted Jun 7, 2017

Participant flow

Active Phase
Participant flow — Active Phase
MilestoneGSK1437173A GroupPlacebo Group
Started7449
Completed6947
Not completed52
Withdrew: Serious adverse event10
Withdrew: Withdrawal by subject21
Withdrew: Migrated/moved from study area01
Withdrew: Lost to follow-up20
Extended Safety Follow-up Phase
Participant flow — Extended Safety Follow-up Phase
MilestoneGSK1437173A GroupPlacebo Group
Started7449
Completed6745
Not completed74
Withdrew: Serious adverse event10
Withdrew: Withdrawal by subject22
Withdrew: Migrated/moved from study area21
Withdrew: Lost to follow-up20
Withdrew: Other-subjects business reasons01

Outcome measures

PrimaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From Month 0 to Month 18
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsGSK1437173A GroupPlacebo Group
Number of Subjects With Serious Adverse Events (SAEs)62
PrimaryNumber of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From screening (up to 21 days prior to Month 0) until Month 18
Reported as:
Count of participants · Participants
Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine
ParticipantsGSK1437173A GroupPlacebo Group
Number of Subjects With SAEs Related to Study Participation or to a Concurrent GSK Medication/Vaccine00
PrimaryNumber of Subjects With Any Fatal SAEs

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
From screening (up to 21 days prior to Month 0) until Month 18
Reported as:
Count of participants · Participants
Number of Subjects With Any Fatal SAEs
ParticipantsGSK1437173A GroupPlacebo Group
Number of Subjects With Any Fatal SAEs00
PrimaryNumber of Subjects With Any Adverse Events (AEs) of Specific Interest

AEs of specific interest include new onset of autoimmune diseases (NOADs) and other immune mediated inflammatory disorders from administration of the first dose of vaccine/placebo.

Time frame:
From Month 0 until Month 18
Reported as:
Count of participants · Participants
Number of Subjects With Any Adverse Events (AEs) of Specific Interest
ParticipantsGSK1437173A GroupPlacebo Group
Number of Subjects With Any Adverse Events (AEs) of Specific Interest00
PrimaryNumber of Subjects With Any, Grade 3 and Related Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = incidence of a particular symptom regardless of their intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.

Time frame:
Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited Local Symptoms
ParticipantsGSK1437173A GroupPlacebo Group
Any Pain, Dose 1694
Grade 3 Pain, Dose 140
Any Redness, Dose 1170
Grade 3 Redness, Dose 120
Any Swelling, Dose 1120
Grade 3 Swelling, Dose 110
Any Pain, Dose 2573
Grade 3 Pain, Dose 280
Any Redness, Dose 2190
Grade 3 Redness, Dose 210
Any Swelling, Dose 2110
Grade 3 Swelling, Dose 200
Any Pain, Dose 3431
Grade 3 Pain, Dose 370
Any Redness, Dose 390
Grade 3 Redness, Dose 320
Any Swelling, Dose 350
Grade 3 Swelling, Dose 300
Any Pain, Across doses726
Grade 3 Pain, Across doses120
Any Redness, Across doses280
Grade 3 Redness, Across doses40
Any Swelling, Across doses200
Grade 3 Swelling, Across doses10
PrimaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, gastrointestinal (symptoms included nausea, vomiting, diarrhoea and/or abdominal pain), headache, myalgia, shivering and temperature \[defined as oral/axillary temperature above (\>) 37.5 degrees Celsius (°C)\]. Any = incidence of a particular symptom regardless of their intensity grade or relationship to vaccination. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.

Time frame:
Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsGSK1437173A GroupPlacebo Group
Any Fatigue, Dose 13013
Grade 3 Fatigue, Dose 103
Related Fatigue, Dose 1178
Any Gastrointestinal, Dose 1138
Grade 3 Gastrointestinal, Dose 100
Related Gastrointestinal, Dose 166
Any Headache, Dose 12510
Grade 3 Headache, Dose 101
Related Headache, Dose 1166
Any Myalgia, Dose 1346
Grade 3 Myalgia, Dose 140
Related Myalgia, Dose 1266
Any Shivering, Dose 1195
Grade 3 Shivering, Dose 100
Related Shivering, Dose 1115
Any Temperature, Dose 172
Grade 3 Temperature, Dose 100
Related Temperature, Dose 122
Any Fatigue, Dose 2418
Grade 3 Fatigue, Dose 273
Related Fatigue, Dose 2255
Any Gastrointestinal, Dose 2183
Grade 3 Gastrointestinal, Dose 211
Related Gastrointestinal, Dose 281
Any Headache, Dose 2323
Grade 3 Headache, Dose 230
Related Headache, Dose 2181
Any Myalgia, Dose 2334
Grade 3 Myalgia, Dose 211
Related Myalgia, Dose 2242
Any Shivering, Dose 2231
Grade 3 Shivering, Dose 240
Related Shivering, Dose 2171
Any Temperature, Dose 2121
Grade 3 Temperature, Dose 200
Related Temperature, Dose 2100
Any Fatigue, Dose 3366
Grade 3 Fatigue, Dose 371
Related Fatigue, Dose 3243
Any Gastrointestinal, Dose 384
Grade 3 Gastrointestinal, Dose 310
Related Gastrointestinal, Dose 352
Any Headache, Dose 3337
Grade 3 Headache, Dose 341
Related Headache, Dose 3213
Any Myalgia, Dose 3321
Grade 3 Myalgia, Dose 360
Related Myalgia, Dose 3221
Any Shivering, Dose 3201
Grade 3 Shivering, Dose 370
Related Shivering, Dose 3141
Any Temperature, Dose 3111
Grade 3 Temperature, Dose 300
Related Temperature, Dose 360
Any Fatigue, Across doses5514
Grade 3 Fatigue, Across doses124
Related Fatigue, Across doses418
Any Gastrointestinal, Across doses2811
Grade 3 Gastrointestinal, Across doses21
Related Gastrointestinal, Across doses167
Any Headache, Across doses4715
Grade 3 Headache, Across doses62
Related Headache, Across doses348
Any Myalgia, Across doses549
Grade 3 Myalgia, Across doses101
Related Myalgia, Across doses448
Any Shivering, Across doses375
Grade 3 Shivering, Across doses110
Related Shivering, Across doses295
Any Temperature, Across doses223
Grade 3 Temperature, Across doses00
Related Temperature, Across doses172
PrimaryNumber of Subjects With Unsolicited AEs

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
Within 30 days (Days 0-29) after each vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Unsolicited AEs
ParticipantsGSK1437173A GroupPlacebo Group
Any AE(s)4126
Grade 3 AE(s)42
Related AE(s)113
PrimaryNumber of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.

Time frame:
At Screening Visit (up to 21 days prior to Month 0)
Reported as:
Count of participants · Participants
Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges
ParticipantsGSK1437173A GroupPlacebo Group
Alanine Aminotransferase — Unknown00
Alanine Aminotransferase — Below00
Alanine Aminotransferase — Within7041
Alanine Aminotransferase — Above48
Albumin — Unknown00
Albumin — Below00
Albumin — Within7247
Albumin — Above22
Alkaline Phosphatase — Unknown00
Alkaline Phosphatase — Below00
Alkaline Phosphatase — Within7044
Alkaline Phosphatase — Above45
Aspartate Aminotransferase — Unknown00
Aspartate Aminotransferase — Below00
Aspartate Aminotransferase — Within6945
Aspartate Aminotransferase — Above54
Basophils — Unknown00
Basophils — Below00
Basophils — Within7449
Basophils — Above00
White Blood Cells — Unknown10
White Blood Cells — Below30
White Blood Cells — Within6947
White Blood Cells — Above12
Total Bilirubin — Unknown00
Total Bilirubin — Below00
Total Bilirubin — Within6546
Total Bilirubin — Above93
Bilirubin Conjugated / Direct — Unknown00
Bilirubin Conjugated / Direct — Below00
Bilirubin Conjugated / Direct — Within7349
Bilirubin Conjugated / Direct — Above10
Creatinine — Unknown00
Creatinine — Below68
Creatinine — Within6840
Creatinine — Above01
Eosinophils — Unknown00
Eosinophils — Below1410
Eosinophils — Within5938
Eosinophils — Above11
Glucose — Unknown00
Glucose — Below01
Glucose — Within6943
Glucose — Above55
Bicarbonate — Unknown00
Bicarbonate — Below52
Bicarbonate — Within6947
Bicarbonate — Above00
Haemoglobin — Unknown00
Haemoglobin — Below135
Haemoglobin — Within5842
Haemoglobin — Above32
Potassium — Unknown00
Potassium — Below00
Potassium — Within7449
Potassium — Above00
Lymphocytes — Unknown00
Lymphocytes — Below01
Lymphocytes — Within7448
Lymphocytes — Above00
Monocytes — Unknown00
Monocytes — Below24
Monocytes — Within7145
Monocytes — Above10
Sodium — Unknown00
Sodium — Below10
Sodium — Within7349
Sodium — Above00
Neutrophils — Unknown00
Neutrophils — Below53
Neutrophils — Within6945
Neutrophils — Above01
Platelets — Unknown00
Platelets — Below41
Platelets — Within7048
Platelets — Above00
PrimaryNumber of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.

Time frame:
At Month 1
Reported as:
Count of participants · Participants
Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges
ParticipantsGSK1437173A GroupPlacebo Group
Alanine Aminotransferase — Unknown00
Alanine Aminotransferase — Below00
Alanine Aminotransferase — Within6741
Alanine Aminotransferase — Above64
Albumin — Unknown00
Albumin — Below00
Albumin — Within6943
Albumin — Above42
Alkaline Phosphatase — Unknown00
Alkaline Phosphatase — Below00
Alkaline Phosphatase — Within7143
Alkaline Phosphatase — Above22
Aspartate Aminotransferase — Unknown00
Aspartate Aminotransferase — Below00
Aspartate Aminotransferase — Within6942
Aspartate Aminotransferase — Above43
Basophils — Unknown10
Basophils — Below00
Basophils — Within7245
Basophils — Above00
Total Bilirubin — Unknown00
Total Bilirubin — Below00
Total Bilirubin — Within6542
Total Bilirubin — Above83
Bilirubin Conjugated/Direct — Unknown00
Bilirubin Conjugated/Direct — Below00
Bilirubin Conjugated/Direct — Within7344
Bilirubin Conjugated/Direct — Above01
Creatinine — Unknown00
Creatinine — Below47
Creatinine — Within6638
Creatinine — Above30
Eosinophils — Unknown10
Eosinophils — Below136
Eosinophils — Within5739
Eosinophils — Above20
Glucose — Unknown00
Glucose — Below21
Glucose — Within6234
Glucose — Above910
Bicarbonate — Unknown00
Bicarbonate — Below71
Bicarbonate — Within6644
Bicarbonate — Above00
Haemoglobin — Unknown10
Haemoglobin — Below123
Haemoglobin — Within5740
Haemoglobin — Above32
Potassium — Unknown00
Potassium — Below01
Potassium — Within7344
Potassium — Above00
Lymphocytes — Unknown10
Lymphocytes — Below10
Lymphocytes — Within7145
Lymphocytes — Above00
Monocytes — Unknown10
Monocytes — Below63
Monocytes — Within6642
Monocytes — Above00
Sodium — Unknown00
Sodium — Below01
Sodium — Within7344
Sodium — Above00
Neutrophils — Unknown10
Neutrophils — Below83
Neutrophils — Within6440
Neutrophils — Above02
Platelets — Unknown10
Platelets — Below23
Platelets — Within7042
Platelets — Above00
White Blood Cells — Unknown10
White Blood Cells — Below54
White Blood Cells — Within6739
White Blood Cells — Above02
PrimaryNumber of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.

Time frame:
At Month 2
Reported as:
Count of participants · Participants
Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges
ParticipantsGSK1437173A GroupPlacebo Group
Alanine Aminotransferase — Unknown01
Alanine Aminotransferase — Below00
Alanine Aminotransferase — Within6740
Alanine Aminotransferase — Above46
Albumin — Unknown01
Albumin — Below00
Albumin — Within6744
Albumin — Above42
Alkaline Phosphatase — Unknown01
Alkaline Phosphatase — Below00
Alkaline Phosphatase — Within6842
Alkaline Phosphatase — Above34
Aspartate Aminotransferase — Unknown01
Aspartate Aminotransferase — Below00
Aspartate Aminotransferase — Within6743
Aspartate Aminotransferase — Above43
Basophils — Unknown12
Basophils — Below00
Basophils — Within7045
Basophils — Above00
Total Bilirubin — Unknown01
Total Bilirubin — Below00
Total Bilirubin — Within6444
Total Bilirubin — Above72
Bilirubin Conjugated/Direct — Unknown01
Bilirubin Conjugated/Direct — Below00
Bilirubin Conjugated/Direct — Within6946
Bilirubin Conjugated/Direct — Above20
Creatinine — Unknown01
Creatinine — Below57
Creatinine — Within6539
Creatinine — Above10
Eosinophils — Unknown12
Eosinophils — Below97
Eosinophils — Within6137
Eosinophils — Above01
Glucose — Unknown01
Glucose — Below20
Glucose — Within5938
Glucose — Above108
Bicarbonate — Unknown01
Bicarbonate — Below20
Bicarbonate — Within6946
Bicarbonate — Above00
Haemoglobin — Unknown12
Haemoglobin — Below155
Haemoglobin — Within5338
Haemoglobin — Above22
Potassium — Unknown01
Potassium — Below00
Potassium — Within7046
Potassium — Above10
Lymphocytes — Unknown12
Lymphocytes — Below01
Lymphocytes — Within6844
Lymphocytes — Above20
Monocytes — Unknown12
Monocytes — Below44
Monocytes — Within6641
Monocytes — Above00
Sodium — Unknown01
Sodium — Below00
Sodium — Within7046
Sodium — Above10
Neutrophils — Unknown12
Neutrophils — Below71
Neutrophils — Within6343
Neutrophils — Above01
Platelets — Unknown12
Platelets — Below12
Platelets — Within6943
Platelets — Above00
White Blood Cells — Unknown12
White Blood Cells — Below62
White Blood Cells — Within6441
White Blood Cells — Above02
PrimaryNumber of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also staus unknown.

Time frame:
At Month 3
Reported as:
Count of participants · Participants
Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges
ParticipantsGSK1437173A GroupPlacebo Group
Alanine Aminotransferase — Unknown12
Alanine Aminotransferase — Below00
Alanine Aminotransferase — Within6636
Alanine Aminotransferase — Above59
Albumin — Unknown12
Albumin — Below00
Albumin — Within6743
Albumin — Above42
Alkaline Phosphatase — Unknown12
Alkaline Phosphatase — Below00
Alkaline Phosphatase — Within6740
Alkaline Phosphatase — Above45
Aspartate Aminotransferase — Unknown12
Aspartate Aminotransferase — Below00
Aspartate Aminotransferase — Within6841
Aspartate Aminotransferase — Above34
Basophils — Unknown01
Basophils — Below00
Basophils — Within7246
Basophils — Above00
Total Bilirubin — Unknown12
Total Bilirubin — Below00
Total Bilirubin — Within6143
Total Bilirubin — Above102
Bilirubin Conjugated/Direct — Unknown12
Bilirubin Conjugated/Direct — Below00
Bilirubin Conjugated/Direct — Within7044
Bilirubin Conjugated/Direct — Above11
Creatinine — Unknown12
Creatinine — Below57
Creatinine — Within6637
Creatinine — Above01
Eosinophils — Unknown01
Eosinophils — Below125
Eosinophils — Within5941
Eosinophils — Above10
Glucose — Unknown12
Glucose — Below20
Glucose — Within6238
Glucose — Above77
Bicarbonate — Unknown12
Bicarbonate — Below52
Bicarbonate — Within6643
Bicarbonate — Above00
Haemoglobin — Unknown01
Haemoglobin — Below145
Haemoglobin — Within5737
Haemoglobin — Above14
Potassium — Unknown12
Potassium — Below00
Potassium — Within7145
Potassium — Above00
Lymphocytes — Unknown01
Lymphocytes — Below00
Lymphocytes — Within7246
Lymphocytes — Above00
Monocytes — Unknown01
Monocytes — Below66
Monocytes — Within6640
Monocytes — Above00
Sodium — Unknown12
Sodium — Below00
Sodium — Within7145
Sodium — Above00
Neutrophils — Unknown01
Neutrophils — Below65
Neutrophils — Within6639
Neutrophils — Above02
Platelets — Unknown01
Platelets — Below32
Platelets — Within6944
Platelets — Above00
White Blood Cells — Unknown01
White Blood Cells — Below57
White Blood Cells — Within6737
White Blood Cells — Above02
PrimaryNumber of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also status unknown.

Time frame:
At Month 6
Reported as:
Count of participants · Participants
Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges
ParticipantsGSK1437173A GroupPlacebo Group
Alanine Aminotransferase — Unknown00
Alanine Aminotransferase — Below00
Alanine Aminotransferase — Within6741
Alanine Aminotransferase — Above46
Albumin — Unknown00
Albumin — Below00
Albumin — Within6844
Albumin — Above33
Alkaline Phosphatase — Unknown00
Alkaline Phosphatase — Below00
Alkaline Phosphatase — Within6742
Alkaline Phosphatase — Above45
Aspartate Aminotransferase — Unknown00
Aspartate Aminotransferase — Below00
Aspartate Aminotransferase — Within6645
Aspartate Aminotransferase — Above52
Basophils — Unknown21
Basophils — Below00
Basophils — Within6946
Basophils — Above00
Total Bilirubin — Unknown00
Total Bilirubin — Below00
Total Bilirubin — Within6045
Total Bilirubin — Above112
Bilirubin Conjugated/Direct — Unknown00
Bilirubin Conjugated/Direct — Below00
Bilirubin Conjugated/Direct — Within6846
Bilirubin Conjugated/Direct — Above31
Creatinine — Unknown00
Creatinine — Below77
Creatinine — Within6239
Creatinine — Above21
Eosinophils — Unknown21
Eosinophils — Below139
Eosinophils — Within5536
Eosinophils — Above11
Glucose — Unknown00
Glucose — Below11
Glucose — Within6237
Glucose — Above89
Bicarbonate — Unknown00
Bicarbonate — Below77
Bicarbonate — Within6340
Bicarbonate — Above10
Haemoglobin — Unknown21
Haemoglobin — Below136
Haemoglobin — Within5537
Haemoglobin — Above13
Potassium — Unknown00
Potassium — Below00
Potassium — Within7047
Potassium — Above00
Lymphocytes — Unknown21
Lymphocytes — Below43
Lymphocytes — Within6542
Lymphocytes — Above01
Monocytes — Unknown21
Monocytes — Below24
Monocytes — Within6742
Monocytes — Above00
Sodium — Unknown00
Sodium — Below00
Sodium — Within7147
Sodium — Above00
Neutrophils — Unknown21
Neutrophils — Below55
Neutrophils — Within6437
Neutrophils — Above04
Platelets — Unknown21
Platelets — Below22
Platelets — Within6744
Platelets — Above00
White Blood Cells — Unknown21
White Blood Cells — Below64
White Blood Cells — Within6239
White Blood Cells — Above13
PrimaryNumber of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges

The assessed parameters were Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Basophils, Bilirubin Total, Bilirubin Conjugated / Direct, Creatinine, Eosinophils, Glucose, Bicarbonate, Haemoglobin, Potassium, Lymphocytes, Monocytes, Sodium, Neutrophils, Platelets and White Blood Cells. Tabulation was made by relation to the normal laboratory ranges: below, within or above, and also staus unknown.

Time frame:
At Month 7
Reported as:
Count of participants · Participants
Number of Subjects With Any Hematological and Biochemical Parameters Below, Within or Above Normal Laboratory Ranges
ParticipantsGSK1437173A GroupPlacebo Group
Alanine Aminotransferase — Unknown11
Alanine Aminotransferase — Below00
Alanine Aminotransferase — Within6442
Alanine Aminotransferase — Above34
Albumin — Unknown11
Albumin — Below01
Albumin — Within6441
Albumin — Above34
Alkaline Phosphatase — Unknown11
Alkaline Phosphatase — Below00
Alkaline Phosphatase — Within6342
Alkaline Phosphatase — Above44
Aspartate Aminotransferase — Unknown11
Aspartate Aminotransferase — Below00
Aspartate Aminotransferase — Within6543
Aspartate Aminotransferase — Above23
Basophils — Unknown00
Basophils — Below00
Basophils — Within6847
Basophils — Above00
Total Bilirubin — Unknown11
Total Bilirubin — Below00
Total Bilirubin — Within5743
Total Bilirubin — Above103
Bilirubin Conjugated/Direct — Unknown11
Bilirubin Conjugated/Direct — Below00
Bilirubin Conjugated/Direct — Within6746
Bilirubin Conjugated/Direct — Above00
Creatinine — Unknown11
Creatinine — Below76
Creatinine — Within5739
Creatinine — Above31
Eosinophils — Unknown00
Eosinophils — Below117
Eosinophils — Within5639
Eosinophils — Above11
Glucose — Unknown11
Glucose — Below00
Glucose — Within6339
Glucose — Above47
Bicarbonate — Unknown11
Bicarbonate — Below64
Bicarbonate — Within6142
Bicarbonate — Above00
Haemoglobin — Unknown00
Haemoglobin — Below196
Haemoglobin — Within4940
Haemoglobin — Above01
Potassium — Unknown11
Potassium — Below10
Potassium — Within6646
Potassium — Above00
Lymphocytes — Unknown00
Lymphocytes — Below01
Lymphocytes — Within6746
Lymphocytes — Above10
Monocytes — Unknown00
Monocytes — Below52
Monocytes — Within6345
Monocytes — Above00
Sodium — Unknown11
Sodium — Below00
Sodium — Within6746
Sodium — Above00
Neutrophils — Unknown00
Neutrophils — Below71
Neutrophils — Within6144
Neutrophils — Above02
Platelets — Unknown00
Platelets — Below21
Platelets — Within6646
Platelets — Above00
White Blood Cells — Unknown00
White Blood Cells — Below61
White Blood Cells — Within6244
White Blood Cells — Above02
PrimaryNumber of Subjects With Any Significant Change in Antiretroviral Therapy (ART), Including Initiation of ART in ART-naïve Subjects

In this analysis, results were tabulated for the main study groups. Significant changes to ART appeared due to failure to control HIV viral load and due to failure to maintain high CD4 cells count.

Time frame:
From Month 0 until Month 18
Reported as:
Count of participants · Participants
Number of Subjects With Any Significant Change in Antiretroviral Therapy (ART), Including Initiation of ART in ART-naïve Subjects
ParticipantsGSK1437173A GroupPlacebo Group
Failure to control HIV viral load00
Failure to maintain high CD4 cells count00
PrimaryNumber of Subjects With Any AIDS-defining Condition

In this analysis, results were tabulated for the main study groups.

Time frame:
From Month 0 until Month 18
Reported as:
Count of participants · Participants
Number of Subjects With Any AIDS-defining Condition
ParticipantsGSK1437173A GroupPlacebo Group
Number of Subjects With Any AIDS-defining Condition00
PrimaryNumber of Subjects With Any Pre-defined Changes in HIV Viral Load (VL) and CD4 T-cell Count

In this analysis, results were tabulated for the main study groups.

Time frame:
From Month 1 to Month 7
Reported as:
Count of participants · Participants
Number of Subjects With Any Pre-defined Changes in HIV Viral Load (VL) and CD4 T-cell Count
ParticipantsGSK1437173A GroupPlacebo Group
Change in HIV viral load31
Change in CD4 cells count74
PrimaryNumber of Subjects With Any Significant Change in Antiretroviral Therapy (ART), Including Initiation of ART in ART-naïve Subjects, by HIV Status

In this analysis, results were tabulated by HIV status

Time frame:
From Month 0 to Month 18
Reported as:
Count of participants · Participants
Number of Subjects With Any Significant Change in Antiretroviral Therapy (ART), Including Initiation of ART in ART-naïve Subjects, by HIV Status
ParticipantsAntiretroviral Therapy (ART) High CD4 Cohort - GSK 1437173AART High CD4 Cohort - PlaceboART Low CD4 Cohort - GSK 1437173AART Low CD4 Cohort - PlaceboNon-ART High CD4 Cohort - GSK 1437173ANon-ART High CD4 Cohort - Placebo
Due to failure to control HIV viral load000000
Due to failure to maintain high CD4 cells count000000
PrimaryNumber of Subjects With Any AIDS-defining Condition, by HIV Status

In this analysis, results were tabulated by HIV status

Time frame:
From Month 0 to Month 18
Reported as:
Count of participants · Participants
Number of Subjects With Any AIDS-defining Condition, by HIV Status
ParticipantsAntiretroviral Therapy (ART) High CD4 Cohort - GSK 1437173AART High CD4 Cohort - PlaceboART Low CD4 Cohort - GSK 1437173AART Low CD4 Cohort - PlaceboNon-ART High CD4 Cohort - GSK 1437173ANon-ART High CD4 Cohort - Placebo
Number of Subjects With Any AIDS-defining Condition, by HIV Status000000
PrimaryNumber of Subjects With Any Pre-defined Changes in HIV Viral Load (VL) and CD4 T-cell Count, by HIV Status

In this analysis, results were tabulated by HIV status.

Time frame:
From Month 1 to Month 7
Reported as:
Count of participants · Participants
Number of Subjects With Any Pre-defined Changes in HIV Viral Load (VL) and CD4 T-cell Count, by HIV Status
ParticipantsAntiretroviral Therapy (ART) High CD4 Cohort - GSK 1437173AART High CD4 Cohort - PlaceboART Low CD4 Cohort - GSK 1437173AART Low CD4 Cohort - PlaceboNon-ART High CD4 Cohort - GSK 1437173ANon-ART High CD4 Cohort - Placebo
Change in HIV viral load101011
Change in CD4 cells count531110
PrimaryFrequency of gE-specific CD4 T-cells

The analysis focused on CD4 T-cells expressing at least 2 cytokines (among interferon-gamma (IFN-g) , interleukin-2 (IL-2), tumour necrosis factor-alpha (TNF-a) and/or CD40 ligand (CD40L)) as determined by in vitro intracellular cytokine staining (ICS) at Month 7 in ART and non-ART cohorts presenting high CD4 counts at enrollment.

Time frame:
At Month 7
Reported as:
Mean · CD4 T-cells/million T-cells
Frequency of gE-specific CD4 T-cells
CD4 T-cells/million T-cellsGSK1437173A GroupPlacebo Group
Frequency of gE-specific CD4 T-cells4684.50 ± 5376.83158.64 ± 151.15
Primary-Anti-gE Antibody (Ab) Concentrations

-Anti-gE antibody (Ab) concentrations were determined by Enzyme-Linked Immunosorbent Assay (ELISA) at Month 7 in ART and non-ART cohorts presenting high CD4 counts at enrolment. Antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in milli-international units per milliliter (mIU/mL).

Time frame:
At Month 7
Reported as:
Geometric mean · mIU/mL
-Anti-gE Antibody (Ab) Concentrations
mIU/mLGSK1437173A GroupPlacebo Group
-Anti-gE Antibody (Ab) Concentrations63812.6 (51183.6 to 79557.7)1028.4 (658.9 to 1605.0)
Secondary-Frequencies of Varicella-Zoster Virus (VZV)- and gE-specific CD4 T-cells

The analysis focused on CD4 T cells expressing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L as determined by ICS at Months 0, 1, 2, 3, 6, 7 and 18 and tabulated for the main study groups.

Time frame:
At Month 0, 1, 2, 3, 6, 7 and 18
Reported as:
Mean · CD4 T-cells/million T-cells
-Frequencies of Varicella-Zoster Virus (VZV)- and gE-specific CD4 T-cells
CD4 T-cells/million T-cellsGSK1437173A GroupPlacebo Group
VZV-specific CD4 [2+] T-cells, pre-vaccination750.20 ± 989.36835.80 ± 1949.39
VZV-specific CD4 [2+] T-cells, Month 1768.60 ± 739.68913.87 ± 2262.66
VZV-specific CD4 [2+] T-cells, Month 2734.09 ± 680.34874.13 ± 2027.95
VZV-specific CD4 [2+] T-cells, Month 31878.81 ± 1615.20987.24 ± 1988.86
VZV-specific CD4 [2+] T-cells, Month 61646.83 ± 1202.32674.20 ± 657.00
VZV-specific CD4 [2+] T-cells, Month 72626.71 ± 2514.401204.44 ± 1911.53
VZV-specific CD4 [2+] T-cells, Month 18995.35 ± 842.96531.24 ± 579.63
gE-specific CD4 [2+] T-cells, pre-vaccination218.26 ± 254.94123.15 ± 170.79
gE-specific CD4 [2+] T-cells, Month 1704.06 ± 614.49132.49 ± 213.05
gE-specific CD4 [2+] T-cells, Month 2649.68 ± 555.51140.95 ± 197.99
gE-specific CD4 [2+] T-cells, Month 33503.69 ± 2971.74160.10 ± 220.32
gE-specific CD4 [2+] T-cells, Month 62647.71 ± 1972.00133.70 ± 137.94
gE-specific CD4 [2+] T-cells, Month 74684.50 ± 5376.83158.64 ± 151.15
gE-specific CD4 [2+] T-cells, Month 181929.30 ± 1603.50139.50 ± 219.57
Secondary-Frequencies of Varicella-Zoster Virus (VZV)- and gE-specific CD4 T-cells, by HIV Status

The analysis focused on CD4 T-cells expressing at least 2 cytokines (among IFN-g, IL-2, TNF-a and/or CD40L as determined by ICS at Months 0, 1, 2, 3, 6, 7 and 18 and tabulated by HIV status.

Time frame:
At Months 0, 1, 2, 3, 6, 7 and 18
Reported as:
Mean · CD4 T-cells/million T-cells
-Frequencies of Varicella-Zoster Virus (VZV)- and gE-specific CD4 T-cells, by HIV Status
CD4 T-cells/million T-cellsAntiretroviral Therapy (ART) High CD4 Cohort - GSK 1437173AART High CD4 Cohort - PlaceboART Low CD4 Cohort - GSK 1437173AART Low CD4 Cohort - PlaceboNon-ART High CD4 Cohort - GSK 1437173ANon-ART High CD4 Cohort - Placebo
VZV-specific CD4 [2+] T-cells, pre-vaccination789.48 ± 1037.59927.27 ± 2053.321.00 ± 0.0086.96 ± NA896.13 ± 749.70112.66 ± 157.91
VZV-specific CD4 [2+] T-cells, Month 1830.78 ± 775.611049.73 ± 2442.95114.79 ± 114.03146.91 ± 142.991049.36 ± 546.09186.38 ± 31.21
VZV-specific CD4 [2+] T-cells, Month 2716.33 ± 699.22991.07 ± 2190.70814.64 ± 920.49329.96 ± 53.46769.13 ± 469.02131.90 ± 185.13
VZV-specific CD4 [2+] T-cells, Month 31973.47 ± 1669.571075.62 ± 2186.451804.94 ± 2350.96408.18 ± 330.781298.35 ± 725.44918.17 ± 1580.86
VZV-specific CD4 [2+] T-cells, Month 61624.32 ± 1161.05786.72 ± 657.241996.37 ± 1937.58136.42 ± NA1160.93 ± NA42.92 ± 37.09
VZV-specific CD4 [2+] T-cells, Month 72285.90 ± 1998.161261.84 ± 1946.126235.67 ± 4334.14113.88 ± NA660.88 ± NA—
VZV-specific CD4 [2+] T-cells, Month 181051.12 ± 816.86599.00 ± 587.08853.05 ± 1235.35580.71 ± 683.08634.55 ± 933.5419.77 ± 22.14
gE-specific CD4 [2+] T-cells, pre-vaccination215.99 ± 266.22136.29 ± 176.8551.15 ± 70.921.00 ± NA350.86 ± 161.9626.57 ± 36.17
gE-specific CD4 [2+] T-cells, Month 1682.62 ± 595.89134.21 ± 224.96584.10 ± 652.67161.73 ± 227.30952.65 ± 763.2484.33 ± 117.84
gE-specific CD4 [2+] T-cells, Month 2610.30 ± 558.27157.92 ± 208.48960.39 ± 632.8694.19 ± 131.79629.54 ± 513.991.00 ± 0.00
gE-specific CD4 [2+] T-cells, Month 33722.21 ± 2789.70190.58 ± 233.814754.94 ± 6004.051.00 ± 0.001310.76 ± 670.5695.71 ± 164.04
gE-specific CD4 [2+] T-cells, Month 62386.40 ± 1571.28152.52 ± 141.505403.79 ± 3326.0397.99 ± NA912.30 ± NA1.00 ± 0.00
gE-specific CD4 [2+] T-cells, Month 73649.92 ± 3112.69166.94 ± 150.5414925.30 ± 10934.071.00 ± NA861.21 ± NA—
gE-specific CD4 [2+] T-cells, Month 182071.17 ± 1583.58159.05 ± 239.502035.18 ± 2100.82109.97 ± 93.90709.62 ± 1011.0324.81 ± 47.63
Secondary-Anti-VZV and Anti-gE Antibody Concentrations

Antibody concentrations were as determined by ELISA and tabulated for the main study groups. Anti-VZV and anti-gE antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL.

Time frame:
At Months 0, 1, 2, 3, 6, 7 and 18
Reported as:
Geometric mean · mIU/mL
-Anti-VZV and Anti-gE Antibody Concentrations
mIU/mLGSK1437173A GroupPlacebo Group
Anti-VZV, Pre-vaccination1292.7 (999.8 to 1671.4)1074.7 (672.7 to 1717.0)
Anti-VZV, Month 16953.8 (5425.1 to 8913.3)1173.8 (762.9 to 1805.8)
Anti-VZV, Month 25170.9 (4032.7 to 6630.4)987.6 (596.3 to 1635.8)
Anti-VZV, Month 311119.7 (9190.8 to 13453.3)1037.8 (620.2 to 1736.5)
Anti-VZV, Month 68244.0 (6678.6 to 10176.3)1069.8 (653.3 to 1751.7)
Anti-VZV, Month 714560.8 (11849.0 to 17893.1)999.3 (598.3 to 1669.2)
Anti-VZV, Month 187493.3 (5926.7 to 9473.9)922.9 (521.1 to 1634.6)
Anti-gE, Pre-vaccination1218.4 (895.0 to 1658.7)849.5 (551.1 to 1309.4)
Anti-gE, Month 124113.2 (18317.4 to 31743.0)1059.0 (749.4 to 1496.5)
Anti-gE, Month 217112.6 (12929.5 to 22649.1)903.3 (590.9 to 1380.9)
Anti-gE, Month 350443.0 (40899.6 to 62213.2)992.9 (647.4 to 1522.6)
Anti-gE, Month 634159.4 (27221.0 to 42866.2)1013.1 (660.5 to 1553.7)
Anti-gE, Month 763812.6 (51183.6 to 79557.7)1028.4 (658.9 to 1605.0)
Anti-gE, Month 1825242.2 (19618.9 to 32477.3)918.0 (588.0 to 1433.1)
Secondary-Anti-VZV and Anti-gE Antibody Concentrations, by HIV Status

Antibody concentrations were as determined by ELISA and tabulated by HIV status. Anti-VZV and anti-gE antibody concentrations were presented as geometric mean concentrations (GMCs) and expressed in mIU/mL.

Time frame:
At Months 0, 1, 2, 3, 6, 7 and 18
Reported as:
Geometric mean · mIU/mL
-Anti-VZV and Anti-gE Antibody Concentrations, by HIV Status
mIU/mLAntiretroviral Therapy (ART) High CD4 Cohort - GSK 1437173AART High CD4 Cohort - PlaceboART Low CD4 Cohort - GSK 1437173AART Low CD4 Cohort - PlaceboNon-ART High CD4 Cohort - GSK 1437173ANon-ART High CD4 Cohort - Placebo
Anti-VZV, Pre-vaccination1161.5 (900.3 to 1498.6)985.1 (568.7 to 1706.4)2272.6 (559.1 to 9236.6)2511.9 (693.0 to 9104.4)1658.0 (315.9 to 8701.1)1068.5 (117.3 to 9735.4)
Anti-VZV, Month 17017.8 (5441.2 to 9051.3)1059.6 (641.1 to 1751.2)6731.0 (572.7 to 79107.0)2871.0 (1386.7 to 5944.3)6706.0 (2477.9 to 18148.5)1167.3 (130.1 to 10475.4)
Anti-VZV, Month 25056.5 (3973.9 to 6434.0)886.9 (498.6 to 1577.4)5649.6 (418.4 to 76276.9)2902.1 (1.9 to 4493973)6100.0 (480.4 to 77462.7)1191.1 (119.6 to 11860.7)
Anti-VZV, Month 311631.9 (9523.8 to 14206.6)1002.7 (565.8 to 1777.1)9110.7 (2224.8 to 37308.9)2479.3 (NA to NA)8990.7 (5233.1 to 15446.6)1062.0 (81.1 to 13906.2)
Anti-VZV, Month 69027.6 (7225.1 to 11279.6)957.0 (537.2 to 1705.0)7634.7 (2054.6 to 28369.5)3164.8 (510.5 to 19621.7)4384.3 (2322.5 to 8276.5)1006.3 (115.7 to 8754.6)
Anti-VZV, Month 715278.5 (12420.2 to 18794.5)930.5 (511.6 to 1692.3)14763.2 (2859.6 to 76216.1)2177.3 (8.7 to 544573.1)8845.8 (5463.6 to 14321.5)1076.7 (109.5 to 10591.1)
Anti-VZV, Month 188242.2 (6484.1 to 10476.9)838.1 (435.9 to 1611.5)6106.2 (748.6 to 49809.5)1955.3 (188.8 to 20249.5)4361.7 (1721.5 to 11050.9)1209.2 (13.9 to 105230.8)
Anti-gE, Pre-vaccination1113.2 (794.3 to 1560.3)791.0 (490.7 to 1275.1)1845.1 (465.1 to 7319.1)2420.7 (512.0 to 11445.2)1748.6 (308.5 to 9912.2)661.2 (43.8 to 9984.8)
Anti-gE, Month 125530.6 (19158.6 to 34021.9)1029.5 (719.5 to 1473.1)18767.2 (2219.4 to 158697.1)2328.1 (446.4 to 12141.8)18742.3 (6616.7 to 53089.1)720.0 (50.6 to 10238.5)
Anti-gE, Month 218208.6 (13537.4 to 24491.6)839.8 (524.6 to 1344.4)13106.4 (1619.0 to 106104.2)2465.5 (561.9 to 10817.4)13100.6 (4828.6 to 35543.7)735.0 (52.7 to 10245.9)
Anti-gE, Month 354777.7 (44077.1 to 68076.1)955.6 (590.6 to 1546.2)36592.6 (7026.0 to 190581.1)2166.3 (618.9 to 7583.1)33662.4 (20665.6 to 54833.0)736.6 (52.1 to 10414.5)
Anti-gE, Month 638068.2 (29964.3 to 48363.7)932.8 (582.6 to 1493.3)24725.0 (5143.2 to 118862.3)2629.2 (561.7 to 12306.8)18189.6 (11258.0 to 29389.0)920.6 (54.8 to 15461.5)
Anti-gE, Month 771309.6 (57019.3 to 89181.5)928.8 (566.8 to 1522.1)47382.6 (9151.2 to 245336.2)2553.0 (610.1 to 10683.1)32334.6 (17277.6 to 60513.4)1087.6 (60.2 to 19641.4)
Anti-gE, Month 1828854.6 (22512.5 to 36983.3)849.4 (514.6 to 1401.9)18995.8 (1733.3 to 208181.4)1953.7 (572.7 to 6665.3)10869.2 (4435.4 to 26635.7)757.8 (34.8 to 16519.1)
SecondaryNumber of Subjects With Any Herpes Zoster (HZ) Cases and Complications
Time frame:
From Month 0 until Month 18
Reported as:
Count of participants · Participants
Number of Subjects With Any Herpes Zoster (HZ) Cases and Complications
ParticipantsGSK1437173A GroupPlacebo Group
Number of Subjects With Any Herpes Zoster (HZ) Cases and Complications10
SecondaryCD4 Count

CD4 count was tabulated by HIV status.

Time frame:
At Screening Visit (up to 21 days prior to Month 0), Months 1, 2, 3, 6, 7 and 18
Reported as:
Mean · CD4 T-cells/million T-cells
CD4 Count
CD4 T-cells/million T-cellsAntiretroviral Therapy (ART) High CD4 Cohort - GSK 1437173AART High CD4 Cohort - PlaceboART Low CD4 Cohort - GSK 1437173AART Low CD4 Cohort - PlaceboNon-ART High CD4 Cohort - GSK 1437173ANon-ART High CD4 Cohort - Placebo
CD4+, pre-vaccination631.46 ± 236.36683.39 ± 228.29152.11 ± 38.39132.20 ± 11.19805.33 ± 132.38901.67 ± 177.61
CD4+, Month 1630.55 ± 241.78694.69 ± 307.98151.11 ± 38.72163.00 ± 53.66879.67 ± 277.37773.40 ± 144.85
CD4+, Month 2667.69 ± 309.22656.14 ± 262.43131.13 ± 39.57133.75 ± 31.86808.75 ± 211.32804.00 ± 199.09
CD4+, Month 3633.60 ± 228.75640.14 ± 238.05153.11 ± 54.27142.60 ± 36.49783.63 ± 239.92762.60 ± 185.66
CD4+, Month 6655.02 ± 264.67668.28 ± 308.64145.33 ± 29.74145.20 ± 43.18776.43 ± 303.301082.80 ± 649.82
CD4+, Month 7654.69 ± 271.31658.81 ± 246.53170.25 ± 44.52150.40 ± 35.11869.14 ± 297.04866.00 ± 144.30
CD4+, Month 18679.71 ± 247.57651.06 ± 247.30168.43 ± 58.49151.40 ± 57.48720.00 ± 228.77824.40 ± 207.57
SecondaryHIV VL

HIV VL was tabulated by HIV status, for subjects with a number of available results greater than or equal to (≥) 40 copies/mL.

Time frame:
At Screening Visit (up to 21 days prior to Month 0), Months 1, 2, 3, 6, 7 and 18
Reported as:
Mean · HIV-RNA copies/mL
HIV VL
HIV-RNA copies/mLAntiretroviral Therapy (ART) High CD4 Cohort - GSK 1437173AART High CD4 Cohort - PlaceboART Low CD4 Cohort - GSK 1437173AART Low CD4 Cohort - PlaceboNon-ART High CD4 Cohort - GSK 1437173ANon-ART High CD4 Cohort - Placebo
HIV VL, pre-vaccination——62.00 ± NA—23014.11 ± 18435.1016022.17 ± 23652.18
HIV VL, Month 142.00 ± NA—48.00 ± NA—24538.89 ± 19056.1014415.80 ± 9289.92
HIV VL, Month 248.67 ± 10.7955.00 ± NA48.00 ± 2.83—24134.25 ± 13753.9218188.25 ± 15199.35
HIV VL, Month 375.00 ± 37.75—84.00 ± NA—19453.50 ± 11878.7416270.00 ± 15785.91
HIV VL, Month 619699.25 ± 39272.50112.00 ± NA66053.50 ± 93328.9051.00 ± NA37091.29 ± 33678.6046429.60 ± 52567.42
HIV VL, Month 7530.67 ± 785.5055.75 ± 6.29248.00 ± NA—35534.00 ± 39549.4225774.60 ± 27360.66
HIV VL, Month 1870.33 ± 29.5492.67 ± 64.5348.00 ± NA—60597.00 ± 48313.1514742.60 ± 18306.17

Adverse events

Collected over Solicited local and general symptoms: within 7 days (Days 0-6) post-vaccination. Unsolicited Adverse Events (AEs): within 30 days (Days 0-29) post-vaccination. Serious Adverse Events (SAEs): during the entire study period (from Month 0 up to Month 18).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK1437173A Group0/74 (0%)6/74 (8.1%)72/74 (97.3%)
Placebo Group0/49 (0%)2/49 (4.1%)29/49 (59.2%)
Most frequent serious events
Most frequent serious events
EventGSK1437173A GroupPlacebo Group
Drug abusePsychiatric disorders0/741/49
Peripheral vascular disorderVascular disorders0/741/49
Anal abscessInfections and infestations1/740/49
Coronary artery diseaseCardiac disorders1/740/49
EpididymitisReproductive system and breast disorders1/740/49
Laryngeal cancer recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/740/49
Oesophageal varices haemorrhageGastrointestinal disorders1/740/49
Partial seizuresNervous system disorders1/740/49
Portal hypertensionHepatobiliary disorders1/740/49
Most frequent other events
Showing 10 of 13
Most frequent other events
EventGSK1437173A GroupPlacebo Group
PainGeneral disorders72/736/48
FatigueGeneral disorders55/7314/48
MyalgiaGeneral disorders54/739/48
HeadacheGeneral disorders47/7315/48
ShiveringGeneral disorders37/735/48
RednessGeneral disorders28/730/48
GastrointestinalGeneral disorders28/7311/48
TemperatureGeneral disorders22/733/48
SwellingGeneral disorders20/730/48
Influenza like illnessGeneral disorders6/741/49

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK1437173A GroupPlacebo GroupTotal
Mean46.6 ± 10.6845.1 ± 11.3646.0 ± 10.93
Sex: Female, Male
Sex: Female, Male(Participants)GSK1437173A GroupPlacebo GroupTotal
Female527
Male6947116
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK1437173A GroupPlacebo GroupTotal
African heritage/African American628
Asian-East Asian heritage011
Asian-Japanese heritage101
White-Caucasian/European heritage6642108
Unspecified145
08

Study locations

15 sites
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    San Francisco, California 94115, United States
  • GSK Investigational Site
    Orlando, Florida 32803, United States
  • GSK Investigational Site
    Santa Fe, New Mexico 87505, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Hannover, Niedersachsen 30625, Germany
  • GSK Investigational Site
    Bochum, Nordrhein-Westfalen 44791, Germany
  • GSK Investigational Site
    Duesseldorf, Nordrhein-Westfalen 40237, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45122, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Hamburg, 20146, Germany
  • GSK Investigational Site
    Woolwich, London, London SE18 4QH, United Kingdom
  • GSK Investigational Site
    London, E1 1BB, United Kingdom
  • GSK Investigational Site
    London, NW3 2QG, United Kingdom
  • GSK Investigational Site
    London, SW10 9TH, United Kingdom
09

References and documents

Publications

  • Berkowitz EM, Moyle G, Stellbrink HJ, Schurmann D, Kegg S, Stoll M, El Idrissi M, Oostvogels L, Heineman TC; Zoster-015 HZ/su Study Group. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015 Apr 15;211(8):1279-87. doi: 10.1093/infdis/jiu606. Epub 2014 Nov 3. PubMed 25371534 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2010 to primary completion in Jul 2012, 21 months.

Results were first posted in Jun 2017, 4 years 11 months after primary completion. A results delay was requested in Apr 2013.

Of 22 phase 2 interventional studies under Herpes Zoster, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 27. This study's 21 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2010
First posted
Jul 19, 2010
StartActual
Sep 30, 2010
Primary completionActual
Jul 6, 2012
CompletionActual
May 14, 2013
Results delay requested
Apr 11, 2013
Results first posted
Jun 7, 2017
Last update
Apr 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01165203
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 19, 2010
Start date
Sep 30, 2010
Primary completion
Jul 6, 2012
Completion
May 14, 2013
Results posted
Jun 7, 2017
Last update
Apr 30, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Shingrix

Start the discussion